EU panels backs approval of Ariad's Iclusig for leukemia

03/25/2013 | American City Business Journals

Ariad Pharmaceuticals' Iclusig, or ponatinib, was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for chronic, accelerated or blast-phase chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA